Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results ...Middle East

Topline pivotal data expected for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population in the first half of 2025 in support of anticipated first NDA submission by mid-year 2025 Initiation of ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive...

Read More Details
Finally We wish PressBee provided you with enough information of ( Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results )

Also on site :

• FAQs About Orthopedics Specialty
• Kojamo plc's Interim Report 1 January-31 March 2025
• Bomb threat at Jaipur’s SMS Stadium amid India-Pak tensions